BNF 82 (British National Formulary) September 2021: 82: September 2021 - March 2022

Product Information

Different programmes use different referencing styles, but basic principles are the same with two key elements: In-text citations Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice] Many of the unprotected titles used in this book are the titles of the monographs of the European Pharmacopoeia, the British Pharmacopoeia or the British Pharmaceutical Code 1973. In such cases, the products must comply with the standard (if any) of the relevant publication, if necessary. . under the Medicinal Products for Human Use Regulation 2012. Custom titles

As an example, here's a reference for the whole print BNF in Harvard format (remember, though, that you will probably be referencing a specific entry): Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measure Medicines should only be prescribed when they are needed, and in any case the benefits of drug administration should be considered in relation to the associated risk. This is especially important during pregnancy, when the risk to the mother and fetus must be taken into account. It is important to use the latest information on BNF for clinical decisions. The BNF printed edition is updated every year in March and September. Monthly updates are provided online through Medicines Complete and the NHS Evidence Portal. More important changes are in the Changes section; The changes are listed on the Internet as cumulative (from one printed edition to the next) and can be printed monthly to reflect major changes since the last print as an auxiliary book for those who use the printed version.The BNF is authored by the Joint Formulary Committee and you can access it via our Medicines Complete subscription.

Therapeutic equivalence g Biosimal drugs should be considered therapeutically equivalent to the original biological drug within their permitted designations. h Biosimal drugs are generally licensed for all indications of biological drug development, but are subject to evidence submitted to the EMA for approval and must be scientifically substantiated by proven or extrapolated agreement. Prescribing and administering The choice of prescribing a biosimal drug or a drug of biological origin is up to the physician in consultation with the patient. g Biological drugs (including biosimal drugs) must be prescribed and labeled to prevent prescription. Automatic label exchange at the point of delivery is not suitable for biological medicines. Shortened to subtitles A biosilar drug is a biological drug that is very similar and clinically equivalent (in terms of quality, safety and efficacy) to an existing biological drug already approved by the European Union (known as the reference biological drug of origin). The active substance of a biosimal drug is similar but not identical to the biological origin of the drug. Once a biological drug patent expires, the biosimal drug can be authorized by the European Medicines Agency (EMA). A biosilar drug is not the same as a generic that has a simpler molecular structure similar to the original drug. Physical Examination Procedures for Advanced Practitioners and Non-Medical Prescribers - 2nd ed. (2015) Drug information is taken from the manufacturers' product literature, medical and pharmaceutical literature, UK health departments, regulators and professional bodies. The advice is taken from the clinical literature and reflects, where possible, evaluations of evidence from a variety of sources. BNF also considers national guidelines and increased safety care to be authoritative. In addition, the newsroom received advice in all areas of treatment from specialist clinics; this ensures that BNF's recommendations are relevant to practice.

Biologics, Biosimilars and Biobetters: An Introduction for Pharmacists, Physicians and other Health Practitioners(2021) An integral part of the UK’s healthcare infrastructure and relied on by health professionals who prescribe, dispense, and administer medicines globally. Containing guidance on best practice in prescribing, as well as legal and ethical considerations, BNF supports safe and effective decision-making at the point of care.

Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. Mylan (2020) Acamprosate 333 mg Gastro-resistant Tablets SmPC. Available at: https://www.medicines.org.uk/emc/product/2729/smpc (Accessed: 4 December 2020). On all programmes, it is essential to reference everything you use in your written work. Any time you quote from, summarise, paraphrase or discuss something you have read, listened to or watched, you should reference it. This tells the reader where your information comes from, and it ensures that you are not plagiarising (using someone else's words or work without credit). Mylan. Acamprosate 333 mg Gastro-resistant Tablets SmPC. 2020 [cited 2020 Dec 4]Available from: https://www.medicines.org.uk/emc/product/2729/smpcPharmaceutical Excipients: Properties, Functionality and Applications in Research and Industry (2017)